Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients

BACKGROUND: Biomarkers predicting immunotherapy response in metastatic renal cell cancer (mRCC) are lacking. PD-L1 immunohistochemistry is a complementary diagnostic for immune checkpoint inhibitors (ICIs) in mRCC, but has shown minimal clinical utility and is not used in routine clinical practice....

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncoimmunology
Hoofdauteurs: Zhang, Tian, Pabla, Sarabjot, Lenzo, Felicia L., Conroy, Jeffrey M., Nesline, Mary K., Glenn, Sean T., Papanicolau-Sengos, Antonios, Burgher, Blake, Giamo, Vincent, Andreas, Jonathan, Wang, Yirong, Bshara, Wiam, Madden, Katherine G., Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J., Gupta, Rajan, Zhu, Jason, Labriola, Matthew, McCall, Shannon, George, Daniel J., Ghatalia, Pooja, Dayyani, Farshid, Edwards, Robert, Park, Michelle S, Singh, Rajbir, Jacob, Robin, George, Saby, Xu, Bo, Zibelman, Matthew, Kurzrock, Razelle, Morrison, Carl
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Taylor & Francis 2020
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458647/
https://ncbi.nlm.nih.gov/pubmed/32923131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1773200
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items